Biohaven Ltd. 8-K

What Happened
Biohaven Ltd. announced on May 4, 2026 that it entered into Amendment No. 2 to its Equity Distribution Agreement with J.P. Morgan Securities LLC, authorizing an “at-the-market” (ATM) program to sell up to $350.0 million of its common shares. The ATM program is being offered under an effective shelf registration statement (File No. 333-295531) and may be executed through ordinary brokers’ transactions on the NYSE or negotiated sales.

Key Details

• Amendment No. 2 executed May 4, 2026 with J.P. Morgan Securities LLC as manager.
• Aggregate offering size: up to $350.0 million of common shares.
• Offerings will be made under an effective shelf registration statement (filed May 4, 2026) and a prospectus supplement.
• Actual share sales, timing and amounts depend on market conditions, share price, and Biohaven’s capital needs.

Why It Matters
This ATM program gives Biohaven flexible access to capital: the company can raise funds over time without pricing a large overnight offering. For investors, it means potential share dilution if and when the company sells shares under the program; however, the filing does not require immediate sales. The size and timing of any issuance will depend on Biohaven’s funding needs and market conditions.